

Indo-US Clinical Trial of Investigational New Drug SHetA2 for Treatment of Cervical Intraepithelial Neoplasia Novel drug for anti-HPV therapeutics

[Click Here for Detailed EoI Document](#)

About the Technology: SHetA2 selectively targets HPV-driven oncogenesis, with the potency to kill cancer cells while sparing normal cells. It targets mortalin, Hsc70, and Grp78 to disrupt HSP70/E7 complexes, reduce p16 expression, and inhibit tumor growth. SHetA2 has shown strong safety, tolerability, and improved bioavailability in preclinical and Phase 1 studies. Delivered orally or as a vaginal suppository, it offers a cost-effective, non-invasive, take-home therapy, well-suited for global use, including LMICs.

Technology ID: PM-TT-IM-2026-Apr-65

Lead Inventor: Dr. Doris M Benbrook, Dr. Showket Hussain

Institute: ICMR-National Institute of Cancer Prevention and Research (NICPR) Noida

Technology Domain: Drugs

Disease Area (Broad): Non-communicable Diseases
Cancer

EoI Publication Date: 04 May, 2026


EoI Deadline: 20 May, 2026

Need and utility of the Technology from Public health perspective:

SHetA2 inhibits HPV induced tumor growth and shows promising results with low toxicity, in in vitro, preclinical, and ongoing Human Phase-I trial in the US, to support strong relevance for global cervical cancer elimination, especially in LMICs.

Technology Readiness level (TRL):

TRL-5: Available- Phase 1 Trial of OK-1 (SHetA2) in Patients With Advanced or Recurrent Solid Tumors (NCT04928508). (clinicaltrials.gov: NCT04928508)



Validation Status and Study Outcome:

- Inhouse Validation –Complete
- Efficacy Outcome: SHetA2 suppresses cervical cancer growth by inhibiting HR-HPV E6/E7 oncoproteins through disruption of HSP70 interactions.

Market Potential: SHetA2 is a first-in-class, non-destructive therapy for Cervical pre-cancer and cancer lesions are suppressed by inhibiting abnormal cell growth. Unlike current ablative treatments with side-effect risks, SHetA2 aims to prevent cancer progression with no toxicity observed.

Publication: Yes. 10.1002/jmv.70088

IP Filing: NA